<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36100326</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2090-1224</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of advanced research</Title><ISOAbbreviation>J Adv Res</ISOAbbreviation></Journal><ArticleTitle>Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome.</ArticleTitle><Pagination><StartPage>179</StartPage><EndPage>196</EndPage><MedlinePgn>179-196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jare.2021.11.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2090-1232(21)00232-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease (COVID-19) triggers the development of numerous pathologies and infection-linked complications and exacerbates existing pathologies in nearly all body systems. Aside from the primarily targeted respiratory organs, adverse SARS-CoV-2 effects were observed in nervous, cardiovascular, gastrointestinal/metabolic, immune, and other systems in COVID-19 survivors. Long-term effects of this viral infection have been recently observed and represent distressing sequelae recognised by the World Health Organisation (WHO) as a distinct clinical entity defined as post-COVID-19 condition. Considering the pandemic is still ongoing, more time is required to confirm post COVID-19 condition diagnosis in the COVID-19 infected cohorts, although many reported post COVID-19 symptoms overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).</AbstractText><AbstractText Label="AIMS OF REVIEW">In this study, COVID-19 clinical presentation and associated post-infection sequelae (post-COVID-19 condition) were reviewed and compared with ME/CFS symptomatology.</AbstractText><AbstractText Label="KEY SCIENTIFIC CONCEPTS OF REVIEW">The onset, progression, and symptom profile of post COVID-19 condition patients have considerable overlap with ME/CFS. Considering the large scope and range of pro-inflammatory effects of this virus, it is reasonable to expect development of post COVID-19 clinical complications in a proportion of the affected population. There are reports of a later debilitating syndrome onset three months post COVID-19 infection (often described as long-COVID-19), marked by the presence of fatigue, headache, cognitive dysfunction, post-exertional malaise, orthostatic intolerance, and dyspnoea. Acute inflammation, oxidative stress, and increased levels of interleukin-6 (IL-6) and tumor necrosis factor &#x3b1; (TNF&#x3b1;), have been reported in SARS-CoV-2 infected patients. Longitudinal monitoring of post COVID-19 patients is warranted to understand the long-term effects of SARS-CoV-2 infection and the pathomechanism of post COVID-19 condition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Production and hosting by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sukocheva</LastName><ForeName>Olga A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>College of Nursing and Health Sciences, Flinders University of South Australia, Bedford Park 5042, SA, Australia; The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia. Electronic address: olga.sukocheva@flinders.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maksoud</LastName><ForeName>Rebekah</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia; Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beeraka</LastName><ForeName>Narasimha M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Center of Excellence in Molecular Biology and Regenerative Medicine (CEMR), JSS Academy of Higher Education &amp; Research (JSS AHER), Mysore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhunapantula</LastName><ForeName>SabbaRao V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Center of Excellence in Molecular Biology and Regenerative Medicine (CEMR), JSS Academy of Higher Education &amp; Research (JSS AHER), Mysore, India; Special Interest Group in Cancer Biology and Cancer Stem Cells (SIG-CBCSC), JSS Medical College, JSS Academy of Higher Education &amp; Research (JSS AHER), Mysore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinelnikov</LastName><ForeName>Mikhail</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Mohovaya 11c10, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolenko</LastName><ForeName>Vladimir N</ForeName><Initials>VN</Initials><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Mohovaya 11c10, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neganova</LastName><ForeName>Margarita E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klochkov</LastName><ForeName>Sergey G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amjad Kamal</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia; Enzymoics, 7 Peterlee Place, Novel Global Community Educational Foundation, Hebersham, NSW 2770, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staines</LastName><ForeName>Donald R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia; Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall-Gradisnik</LastName><ForeName>Sonya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia; Consortium Health International for Myalgic Encephalomyelitis, National Centre for Neuroimmunology and Emerging Diseases, Griffith University, Gold Coast, QLD, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Adv Res</MedlineTA><NlmUniqueID>101546952</NlmUniqueID><ISSNLinking>2090-1224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Myalgic encephalomyelitis</Keyword><Keyword MajorTopicYN="N">Post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Post-infection</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Sequelae</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>13</Day><Hour>21</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36100326</ArticleId><ArticleId IdType="pmc">PMC8619886</ArticleId><ArticleId IdType="doi">10.1016/j.jare.2021.11.013</ArticleId><ArticleId IdType="pii">S2090-1232(21)00232-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Organization WH. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/; 2021 (accessed 05/08/2021.).</Citation></Reference><Reference><Citation>Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei Q., Wang A.Y., Bryant A., Yang Y., Li M., Wang F., et al. Survival factors and metabolic pathogenesis in elderly patients (&#x2265;65) with COVID-19: a multi-center study. Front Med (Lausanne) 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7873923</ArticleId><ArticleId IdType="pubmed">33585504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Han C., Zhang S., Duan C., Shang H., Bai T., et al. Diarrhea and altered inflammatory cytokine pattern in severe coronavirus disease 2019: impact on disease course and in-hospital mortality. J Gastroenterol Hepatol. 2021;36(2):421&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">32602128</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network &#x2014; United States. Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Group ftGAC-P-ACS. Persistent symptoms in patients after acute COVID-19, JAMA 2020;324(6):603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. The lasting misery of coronavirus long-haulers. Nature. 2020:339&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">32929257</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu B., Xu X., Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154566</ArticleId><ArticleId IdType="pubmed">32290839</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021; 2021.</Citation></Reference><Reference><Citation>Ladds E., Rushforth A., Wieringa S., Taylor S., Rayner C., Husain L., et al. Persistent symptoms after Covid-19: qualitative study of 114 &#x201c;long Covid&#x201d; patients and draft quality principles for services. BMC Health Serv Res. 2020;20(1):1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7750006</ArticleId><ArticleId IdType="pubmed">33342437</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y.M., Shang Y.M., Song W.B., Li Q.Q., Xie H., Xu Q.F., et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health &#x2013; Europe. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Puri B.K., Walker A.J., Maes M., Carvalho A.F., Walder K., et al. Myalgic encephalomyelitis/chronic fatigue syndrome: from pathophysiological insights to novel therapeutic opportunities. Pharmacol Res. 2019;148</Citation><ArticleIdList><ArticleId IdType="pubmed">31509764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey C.M., Louie M., Loeb M., Gold W.L., Muller M.P., de Jager J., et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med. 2007;167(12):1312&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">17592106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong N.S., Zheng B.J., Li Y.M., Poon, Xie Z.H., Chan K.H., et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003;362(9393):1353&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112415</ArticleId><ArticleId IdType="pubmed">14585636</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam M.H., Wing Y.K., Yu M.W., Leung C.M., Ma R.C., Kong A.P., et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169(22):2142&#x2013;2147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky H., Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerwyn M., Maes M. Mechanisms explaining muscle fatigue and muscle pain in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a review of recent findings. Curr Rheumatol Rep. 2017;19(1):1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28116577</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Biehl M., Sese D. Post-intensive care syndrome and COVID-19 - Implications post pandemic. Cleve Clin J Med. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32759175</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasannejad C., Ely E.W., Lahiri S. Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. Crit Care. 2019;23(1):352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6852966</ArticleId><ArticleId IdType="pubmed">31718695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Zoller T., Steinbeis F., et al. Chronic COVID-19 Syndrome and Chronic Fatigue Syndrome (ME/CFS) following the first pandemic wave in Germany &#x2013; a first analysis of a prospective observational study. medRxiv. 2021 2021.02.06.21249256.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. medRxiv. 2020 2020.12.24.20248802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med. 2021;7(1132)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., van de Sande M.I., De Meirleir K.L., Klimas N.G., Broderick G., Mitchell T., et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270(4):327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N., Johnston S.C., Zalewski P., Staines D., Marshall-Gradisnik S. Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study. Qual Life Res. 2020;29(6):1521&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253372</ArticleId><ArticleId IdType="pubmed">31970624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomas C., Newton J. Metabolic abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a mini-review. Biochem Soc Trans. 2018;46(3):547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">29666214</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolson G.L. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. J Cell Biochem. 2007;100(6):1352&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243117</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmion B.P., Sukocheva O., Storm P.A., Lockhart M., Turra M., Kok T., et al. Q fever: persistence of antigenic non-viable cell residues of Coxiella burnetii in the host&#x2013;implications for post Q fever infection fatigue syndrome and other chronic sequelae. QJM. 2009;102(10):673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">19556396</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus S.E., Tosato G., Armstrong G., Lawley T., Preble O.T., Henle W., et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med. 1985;102(1):7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578268</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes G.P., Kaplan J.E., Stewart J.A., Hunt B., Pinsky P.F., Schonberger L.B. A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? JAMA. 1987;257(17):2297&#x2013;2302.</Citation><ArticleIdList><ArticleId IdType="pubmed">3033337</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwald D., Cheney P.R., Peterson D.L., Henry B., Wormsley S.B., Geiger A., et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med. 1992;116(2):103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">1309285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcin S., Kuratsune H., Yamaguchi K., Kitani T., Yamanishi K. Prevalence of human herpesvirus 6 variants A and B in patients with chronic fatigue syndrome. Microbiol Immunol. 1994;38(7):587&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">7968694</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablashi D.V., Eastman H.B., Owen C.B., Roman M.M., Friedman J., Zabriskie J.B., et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol. 2000;16(3):179&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">10738137</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin W.J. Detection of RNA sequences in cultures of a stealth virus isolated from the cerebrospinal fluid of a health care worker with chronic fatigue syndrome. Case report. Pathobiology. 1997;65(1):57&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9200191</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry F., Gow J., Behan P.O. Enterovirus in the chronic fatigue syndrome. Ann Intern Med. 1994;120(11):972&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">8172448</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., Jain A.K., De Meirleir K.L., Peterson D.L., Klimas N.G., Lerner A.M., et al. Myalgic encephalomyelitis/chronic fatigue syndrome. J Chronic Fatigue Syndrome. 2003;11(1):7&#x2013;115.</Citation></Reference><Reference><Citation>Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghali A., Richa P., Lacout C., Gury A., Beucher A.-B., Homedan C., et al. Epidemiological and clinical factors associated with post-exertional malaise severity in patients with myalgic encephalomyelitis/chronic fatigue syndrome. J Transl Med. 2020;18(1):246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309998</ArticleId><ArticleId IdType="pubmed">32571354</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F., Kok K.H., Zhu Z., Chu H., To K.K., Yuan S., et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067204</ArticleId><ArticleId IdType="pubmed">31987001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., To K.K.-W., Wong Y.-C., Liu L., Zhou B., Li X., et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53(4):864&#x2013;877.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402670</ArticleId><ArticleId IdType="pubmed">32791036</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X., Cao Y.Y., Lu X.X., Zhang J.J., Du H., Yan Y.Q., et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699&#x2013;1709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228397</ArticleId><ArticleId IdType="pubmed">32196678</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B., Fan C.Y., Wang A.L., Zou Y.L., Yu Y.H., He C., et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect. 2020;81(1):e51&#x2013;e60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166040</ArticleId><ArticleId IdType="pubmed">32315725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N., Kuo H.H., Boucau J., Farmer J.R., Allard-Chamard H., Mahajan V.S., et al. Loss of Bcl-6-Expressing T follicular helper cells and germinal centers in COVID-19. Cell. 2020;183(1):143&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437499</ArticleId><ArticleId IdType="pubmed">32877699</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M., Honce R., Schultz-Cherry S. Metabolic syndrome and viral pathogenesis: lessons from influenza and coronaviruses. J Virol. 2020;94(18)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7459568</ArticleId><ArticleId IdType="pubmed">32661141</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D., Sharif K., O'Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195002</ArticleId><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Paces J., Strizova Z., Smrz D., Cerny J. COVID-19 and the immune system. Physiol Res. 2020;69(3):379&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648321</ArticleId><ArticleId IdType="pubmed">32469225</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr A.R., Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T., Smith A.I., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2) J Biol Chem. 2005;280(34):30113&#x2013;30119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8062222</ArticleId><ArticleId IdType="pubmed">15983030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou H., Feher A., Davila A.C., Romero M.J., Patel V.S., Kamath V.M., et al. Role of adipose tissue endothelial ADAM17 in age-related coronary microvascular dysfunction. Arterioscler Thromb Vasc Biol. 2017;37(6):1180&#x2013;1193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5484536</ArticleId><ArticleId IdType="pubmed">28473444</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian M., Shen X., Wang H. The distinct role of ADAM17 in APP proteolysis and microglial activation related to Alzheimer's disease. Cell Mol Neurobiol. 2016;36(4):471&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">26119306</ArticleId></ArticleIdList></Reference><Reference><Citation>Sfera A., Osorio C., Zapata Mart&#xed;n Del Campo C.M., Pereida S., Maurer S., Maldonado J.C., Kozlakidis Z. Endothelial senescence and chronic fatigue syndrome, a COVID-19 based hypothesis. Front Cell Neurosci. 2021;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8267916</ArticleId><ArticleId IdType="pubmed">34248502</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteil V., Kwon H., Prado P., Hagelkr&#xfc;ys A., Wimmer R.A., Stahl M., et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905&#x2013;913.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181998</ArticleId><ArticleId IdType="pubmed">32333836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellone M., Calvisi S.L. ACE polymorphisms and COVID-19-related mortality in Europe. J Mol Med (Berl) 2020;98(11):1505&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491982</ArticleId><ArticleId IdType="pubmed">32935155</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell L.M., Harrap S.B., Velkoska E., Patel S.K. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. Clin Sci (Lond) 2013;124(2):65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">23013041</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y., Wang T., Li Y., Guan T., Lai Y., Shen Y., et al. Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. Lipids Health Dis. 2018;17(1):241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195726</ArticleId><ArticleId IdType="pubmed">30342552</ArticleId></ArticleIdList></Reference><Reference><Citation>Delanghe J.R., Speeckaert M.M., De Buyzere M.L. The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta. 2020;505:192&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102561</ArticleId><ArticleId IdType="pubmed">32220422</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y., Kuba K., Ohto-Nakanishi T., Penninger J.M. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 2010;74(3):405&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">20134095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Cai K., Xiong L. Coronavirus disease 2019: A new severe acute respiratory syndrome from Wuhan in China. Acta Virol. 2020;64(2):245&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">32551792</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney E.M., Gurbaxani B.M., Jones J.F., de Souza Coelho L., Pennachin C., Goertzel B.N. Chronic fatigue syndrome and high allostatic load. Pharmacogenomics. 2006;7(3):467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16610956</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A.K., Maloney E.M., Falkenberg V.R., Dimulescu I., Rajeevan M.S. An angiotensin-1 converting enzyme polymorphism is associated with allostatic load mediated by C-reactive protein, interleukin-6 and cortisol. Psychoneuroendocrinology. 2009;34(4):597&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">19081678</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikov A.E., Barbitoff Y.A., Glotov A.S., Danilova M.M., Tonyan Z.N., Nasykhova Y.A., et al. Analysis of the spectrum of ACE2 variation suggests a possible influence of rare and common variants on susceptibility to COVID-19 and severity of outcome. Front Genet. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550667</ArticleId><ArticleId IdType="pubmed">33133145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J., Gong E., Zhang B., Zheng J., Gao Z., Zhong Y., et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213088</ArticleId><ArticleId IdType="pubmed">16043521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Wu H., Yao X., Zhang D., Zhou Y., Fu B., et al. Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm. Cell Mol Immunol. 2021;18(5):1305&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976727</ArticleId><ArticleId IdType="pubmed">33742186</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Martin J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M.D. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol. 2020;20(6):351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186930</ArticleId><ArticleId IdType="pubmed">32303696</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;st R., Cervantes-Barragan L., Habjan M., Maier R., Neuman B.W., Ziebuhr J., et al. Ribose 2&#x2032;-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol. 2011;12(2):137&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182538</ArticleId><ArticleId IdType="pubmed">21217758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y., Zhang W., Zhu Z., Qiao N., Ling Y., Guo M., et al. Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. Cell Discov. 2021;7(1):42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185699</ArticleId><ArticleId IdType="pubmed">34103487</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieman M., Heise M., Baric R. SARS coronavirus and innate immunity. Virus Res. 2008;133(1):101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2292640</ArticleId><ArticleId IdType="pubmed">17451827</ArticleId></ArticleIdList></Reference><Reference><Citation>Totura A.L., Whitmore A., Agnihothram S., Sch&#xe4;fer A., Katze M.G., Heise M.T., et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus. Infection. mBio 2015,;6(3):e00638&#x2013;e715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447251</ArticleId><ArticleId IdType="pubmed">26015500</ArticleId></ArticleIdList></Reference><Reference><Citation>Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32105090</ArticleId></ArticleIdList></Reference><Reference><Citation>Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Transl Res. 2020;226:57&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438210</ArticleId><ArticleId IdType="pubmed">32827705</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanzaro M., Fagiani F., Racchi M., Corsini E., Govoni S., Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255975</ArticleId><ArticleId IdType="pubmed">32467561</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Liu X., Yuan L., Han H., Shereen M.A., Zhen J., et al. Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. Int Immunopharmacol. 2020;86</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318959</ArticleId><ArticleId IdType="pubmed">32619956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon C. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020;20(5):277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132550</ArticleId><ArticleId IdType="pubmed">32249845</ArticleId></ArticleIdList></Reference><Reference><Citation>He L., Zhang Q., Zhang Y., Fan Y., Yuan F., Li S. Single-cell analysis reveals cell communication triggered by macrophages associated with the reduction and exhaustion of CD8(+) T cells in COVID-19. Cell Commun Signal. 2021;19(1):73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8264994</ArticleId><ArticleId IdType="pubmed">34238338</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan H., Lyu Z., Xiao Y., Li C., Wang J., He L., et al. Analysis of the changes of inflammatory cytokine levels in patients with critical coronavirus disease 2019 undergoing invasive mechanical ventilation. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32(9):1051&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">33081889</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dyer A.H., Jones K., Dunne J., Mooney A., Gaffney F., et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornig M., Montoya J.G., Klimas N.G., Levine S., Felsenstein D., Bateman L., et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015;1(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4465185</ArticleId><ArticleId IdType="pubmed">26079000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal A.S., Bradley A.S., Bishop K.N., Kiani-Alikhan S., Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun. 2012;26(1):24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21756995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullington J.M., Hinze-Selch D., Pollm&#xe4;cher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann N Y Acad Sci. 2001;933:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas H.J., Brauch C.M., Settas L., Theoharides T.C. Fibromyalgia&#x2013;new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol. 2006;19(1):5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16569342</ArticleId></ArticleIdList></Reference><Reference><Citation>Moneghetti K.J., Skhiri M., Contrepois K., Kobayashi Y., Maecker H., Davis M., et al. Value of circulating cytokine profiling during submaximal exercise testing in myalgic encephalomyelitis/chronic fatigue syndrome. Sci Rep. 2018;8(1):2779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807550</ArticleId><ArticleId IdType="pubmed">29426834</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbitt M., Eaton-Fitch N., Staines D., Cabanas H., Marshall-Gradisnik S. A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID) BMC Neurology. 2019;19(1):207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6708220</ArticleId><ArticleId IdType="pubmed">31445522</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis. 2014;29(1):19&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">24557875</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas J.L., Palencia T., Fern&#xe1;ndez G., Garc&#xed;a M. Association of T and NK cell phenotype with the diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Front Immunol. 2018;9:1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5954087</ArticleId><ArticleId IdType="pubmed">29867995</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N., du Preez S., Cabanas H., Staines D., Marshall-Gradisnik S. A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. Syst Rev. 2019;8(1):279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6857215</ArticleId><ArticleId IdType="pubmed">31727160</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen C.B., Als&#xf8;e L., Lindvall J.M., Sulheim D., Fagermoen E., Winger A., et al. Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival. J Transl Med. 2017;15(1):102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5426002</ArticleId><ArticleId IdType="pubmed">28494812</ArticleId></ArticleIdList></Reference><Reference><Citation>Milrad S.F., Hall D.L., Jutagir D.R., Lattie E.G., Ironson G.H., Wohlgemuth W., et al. Poor sleep quality is associated with greater circulating pro-inflammatory cytokines and severity and frequency of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) symptoms in women. J Neuroimmunol. 2017;303:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5258835</ArticleId><ArticleId IdType="pubmed">28038892</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Twisk F.N., Kubera M., Ringel K. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-&#x3b1;, PMN-elastase, lysozyme and neopterin. J Affect Disord. 2012;136(3):933&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">21975140</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eeden C., Khan L., Osman M.S., Cohen Tervaert J.W. Natural killer cell dysfunction and its role in COVID-19. Int J Mol Sci. 2020;21(17)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503862</ArticleId><ArticleId IdType="pubmed">32883007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M.A., Kahan S.M., Zajac A.J. Anti-viral CD8 T cells and the cytokines that they love. Virology. 2013;435(1):157&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580945</ArticleId><ArticleId IdType="pubmed">23217625</ArticleId></ArticleIdList></Reference><Reference><Citation>de Candia P., Prattichizzo F., Garavelli S., Matarese G., Cells T. Warriors of SARS-CoV-2 infection. Trends Immunol. 2021;42(1):18&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664351</ArticleId><ArticleId IdType="pubmed">33277181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S.M., Wherry E.J. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity. 2007;27(3):393&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431921</ArticleId><ArticleId IdType="pubmed">17892848</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeidi A., Zandi K., Cheok Y.Y., Saeidi H., Wong W.F., Lee C.Y.Q., et al. T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses. Front Immunol. 2018;9:2569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237934</ArticleId><ArticleId IdType="pubmed">30473697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan S.M., Wherry E.J., Zajac A.J. T cell exhaustion during persistent viral infections. Virology. 2015;479&#x2013;480:180&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4424083</ArticleId><ArticleId IdType="pubmed">25620767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wherry E.J. T cell exhaustion. Nat Immunol. 2011;12(6):492&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">21739672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H.Y., Zhang M., Yang C.X., Zhang N., Wang X.C., Yang X.P., et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091621</ArticleId><ArticleId IdType="pubmed">32203186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Thomas R., Oh J., Su D.M. Thymic aging may be associated with COVID-19 pathophysiology in the elderly. Cells. 2021;10(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8001029</ArticleId><ArticleId IdType="pubmed">33808998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariol A., Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. 2020;53(2):248&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359787</ArticleId><ArticleId IdType="pubmed">32717182</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996&#x2013;1012.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Liu F., et al. Diverse functional autoantibodies in patients with COVID-19. medRxiv. 2021 2020.12.10.20247205.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur J.M., Forrest J.C., Boehme K.W., Kennedy J.L., Owens S., Herzog C., et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS ONE. 2021;16(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Hohberger B., Wenzel K., F&#xfc;rst J., Schulze-Rothe S., Wallukat A., et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C., Ferse C., Kreye J., Reincke S.M., Sanchez-Sendin E., Rocco A., et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021;93:415&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Virhammar J., N&#xe4;&#xe4;s A., F&#xe4;llmar D., Cunningham J.L., Klang A., Ashton N.J., et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol. 2021;28(10):3324&#x2013;3331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518988</ArticleId><ArticleId IdType="pubmed">33369818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F., Blanco J., Capelli E., Castro-Marrero J., Steiner S., Murovska M., et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome &#x2013; Evidence for an autoimmune disease. Autoimmun Rev. 2018;17(6):601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">29635081</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth K., Scheibenbogen C. A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): recognitions from the finding of autoantibodies against &#xdf;2-adrenergic receptors. Autoimmun Rev. 2020;19(6)</Citation><ArticleIdList><ArticleId IdType="pubmed">32247028</ArticleId></ArticleIdList></Reference><Reference><Citation>Results of first successful treatment confirmed with two other Long COVID patients. Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen-N&#xfc;rnberg, Germany; 2021.</Citation></Reference><Reference><Citation>Haberland A., Krylova O., Nikolenko H., G&#xf6;ttel P., Dallmann A., M&#xfc;ller J., et al. Aptamer BC 007's affinity to specific and less-specific anti-SARS-CoV-2 neutralizing antibodies. Viruses. 2021;13(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8157297</ArticleId><ArticleId IdType="pubmed">34069827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bynke A., Julin P., Gottfries C.G., Heidecke H., Scheibenbogen C., Bergquist J. Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients - A validation study in plasma and cerebrospinal fluid from two Swedish cohorts. Brain Behav Immun Health. 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8474431</ArticleId><ArticleId IdType="pubmed">34589868</ArticleId></ArticleIdList></Reference><Reference><Citation>de Las Heras N., Mart&#xed;n Gim&#xe9;nez V.M., Ferder L., Manucha W., Lahera V. Implications of oxidative stress and potential role of mitochondrial dysfunction in COVID-19: therapeutic effects of vitamin D. Antioxidants (Basel) 2020;9(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7555731</ArticleId><ArticleId IdType="pubmed">32967329</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh K.K., Chaubey G., Chen J.Y., Suravajhala P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am J Physiol-Cell Physiol. 2020;319(2):C258&#x2013;C267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381712</ArticleId><ArticleId IdType="pubmed">32510973</ArticleId></ArticleIdList></Reference><Reference><Citation>Burtscher J., Cappellano G., Omori A., Koshiba T., Millet G.P. Mitochondria: in the cross fire of SARS-CoV-2 and immunity. iScience. 2020;23(10):101631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7524535</ArticleId><ArticleId IdType="pubmed">33015593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Li C., Chen S., Zhang X., Wang F., Shi T., et al. Association of body mass index with severity and mortality of COVID-19 pneumonia: a two-center, retrospective cohort study from Wuhan, China. Aging (Albany NY) 2021;13(6):7767&#x2013;7780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034951</ArticleId><ArticleId IdType="pubmed">33761466</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer R., Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev. 2015;2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365363</ArticleId><ArticleId IdType="pubmed">25834699</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh J., Peyssonnaux C., Singh K.K., Edeas M. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion. 2020;54:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837003</ArticleId><ArticleId IdType="pubmed">32574708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolsk E., Mygind H., Gr&#xf8;ndahl T.S., Pedersen B.K., van Hall G. IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am J Physiol Endocrinol Metab. 2010;299(5):E832&#x2013;E840.</Citation><ArticleIdList><ArticleId IdType="pubmed">20823453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondia-Pons I., Ryan L., Martinez J.A. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem. 2012;68(4):701&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">22351038</ArticleId></ArticleIdList></Reference><Reference><Citation>Geltink R.I.K., Kyle R.L., Pearce E.L. Unraveling the complex interplay between T cell metabolism and function. Annu Rev Immunol. 2018;36:461&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323527</ArticleId><ArticleId IdType="pubmed">29677474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibellini L., De Biasi S., Paolini A., Borella R., Boraldi F., Mattioli M., et al. Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol Med. 2020;12(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645870</ArticleId><ArticleId IdType="pubmed">33078545</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro-Garc&#xed;a M.A., Mayo J.C., Sainz R.M., Alonso-Arias R. Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes. Front Immunol. 2018;9:339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839096</ArticleId><ArticleId IdType="pubmed">29545794</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmann N., Finlay D.K. Metabolic regulation of immune responses: therapeutic opportunities. J Clin Invest. 2016;126(6):2031&#x2013;2039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887169</ArticleId><ArticleId IdType="pubmed">27249676</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce E.L., Pearce E.J. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38(4):633&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654249</ArticleId><ArticleId IdType="pubmed">23601682</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Windt G.J., O'Sullivan D., Everts B., Huang S.C., Buck M.D., Curtis J.D., et al. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc Natl Acad Sci U S A. 2013;110(35):14336&#x2013;14341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3761631</ArticleId><ArticleId IdType="pubmed">23940348</ArticleId></ArticleIdList></Reference><Reference><Citation>MacIver N.J., Michalek R.D., Rathmell J.C. Metabolic regulation of T lymphocytes. Annu Rev Immunol. 2013;31:259&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606674</ArticleId><ArticleId IdType="pubmed">23298210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S.S., Wang J., Chen M. Metabolic reprogramming in CD8(+) T cells during acute viral infections. Front Immunol. 2020;11:1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326043</ArticleId><ArticleId IdType="pubmed">32670270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nrich G., Raftery M.J., Samstag Y. Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Adv Biol Regul. 2020;77</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334659</ArticleId><ArticleId IdType="pubmed">32773102</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellheim A., Brekke O.L., Espevik T., Harboe M., Mollnes T.E. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol. 2009;69(6):479&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">19439008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweetman E., Kleffmann T., Edgar C., de Lange M., Vallings R., Tate W. A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction. J Transl Med. 2020;18(1):365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7512220</ArticleId><ArticleId IdType="pubmed">32972442</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G., Maes M. Mitochondria and immunity in chronic fatigue syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2020;103</Citation><ArticleIdList><ArticleId IdType="pubmed">32470498</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Anderson G., Maes M. Hypothalamic-pituitary-adrenal hypofunction in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) as a consequence of activated immune-inflammatory and oxidative and nitrosative pathways. Mol Neurobiol. 2017;54(9):6806&#x2013;6819.</Citation><ArticleIdList><ArticleId IdType="pubmed">27766535</ArticleId></ArticleIdList></Reference><Reference><Citation>Suematsu N., Tsutsui H., Wen J., Kang D., Ikeuchi M., Ide T., et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation. 2003;107(10):1418&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">12642364</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietraforte D., Vona R., Marchesi A., de Jacobis I.T., Villani A., Del Principe D., et al. Redox control of platelet functions in physiology and pathophysiology. Antioxid Redox Signal. 2014;21(1):177&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">24597688</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslamifar Z., Behzadifard M., Soleimani M., Behzadifard S. Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor. Thromb J. 2020;18(1):38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737414</ArticleId><ArticleId IdType="pubmed">33323111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Paz L., Capodanno D., Montalescot G., Angiolillo D.J. Coronavirus disease 2019&#x2013;associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc. 2021;10(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955431</ArticleId><ArticleId IdType="pubmed">33228447</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden S., Maksoud R., Eaton-Fitch N., Cabanas H., Staines D., Marshall-Gradisnik S. A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease. J Transl Med. 2020;18(1):290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392668</ArticleId><ArticleId IdType="pubmed">32727475</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall-Gradisnik S., Huth T., Chacko A., Johnston S., Smith P., Staines D. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome, Appl. Clin Genet. 2016;9:39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821384</ArticleId><ArticleId IdType="pubmed">27099524</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal S., Lee Y. Transient receptor potential channels and metabolism. Mol Cells. 2019;42(8):569&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6715338</ArticleId><ArticleId IdType="pubmed">31446746</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T., Staines D., Nilius B., Smith P., Marshall-Gradisnik S. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients. Biol Res. 2016;49(1):27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888729</ArticleId><ArticleId IdType="pubmed">27245705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet J., Czarlewski W., Zuberbier T., Mullol J., Blain H., Cristol J.-P., et al. Potential interplay between Nrf2, TRPA1, and TRPV1 in nutrients for the control of COVID-19. Int Arch Allergy Immunol. 2021;182(4):324&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018185</ArticleId><ArticleId IdType="pubmed">33567446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuebler W., Jordt S.-E., Liedtke W. COVID-19: urgent reconsideration of lung edema as a preventable outcome: inhibition of TRPV4 as a promising and feasible approach. SSRN. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276984</ArticleId><ArticleId IdType="pubmed">32401673</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana A., Hoth M. Mitochondrial dynamics and their impact on T cell function. Cell Calcium. 2012;52(1):57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">22425631</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Chen D., Wang L., Zhao Y., Wei L., Chen Z., et al. Low serum calcium: a new, important indicator of COVID-19 patients from mild/moderate to severe/critical. Biosci Rep. 2020;40(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755121</ArticleId><ArticleId IdType="pubmed">33252122</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespi B., Alcock J. Conflicts over calcium and the treatment of COVID-19. Evol Med Public Health. 2021;9(1):149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717197</ArticleId><ArticleId IdType="pubmed">33732462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Li X., Geng D., Mei N., Wu P.Y., Huang C.C., et al. Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7396952</ArticleId><ArticleId IdType="pubmed">32838240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindan C.E., Mankad K., Ram D., Kociolek L.K., Silvera V.M., Boddaert N., et al. Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. Lancet Child Adolescent Health. 2021;5(3):167&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744016</ArticleId><ArticleId IdType="pubmed">33338439</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M., Ciccarelli M., Cecconi M., Aghemo A., Morelli P., Gelardi F., et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [(18)F]FDG-PET/CT study. Eur J Nucl Med Mol Imaging. 2021;48(5):1460&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7595761</ArticleId><ArticleId IdType="pubmed">33123760</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J., Radke J., Dittmayer C., Franz J., Thomas C., Mothes R., et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24(2):168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D., Selvakumar G.P., Ahmed M.E., Raikwar S.P., Thangavel R., Khan A., et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020;26(5&#x2013;6):402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">32684080</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin R., Riste L., Hann M., Walther A., Mukherjee A., Heald A. Into the looking glass: post-viral syndrome post COVID-19. Med Hypotheses. 2020;144</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320866</ArticleId><ArticleId IdType="pubmed">32758891</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein D.S. The extended autonomic system, dyshomeostasis, and COVID-19. Clin Auton Res. 2020;30(4):299&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7374073</ArticleId><ArticleId IdType="pubmed">32700055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N., Dantzer R., Khandaker G.M. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza M.G., De Lorenzo R., Conte C., Poletti S., Vai B., Bollettini I., et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., Islam M.F., Conroy K., Cotler J., Torres C., Johnson M., et al. COVID-19 symptoms over time: comparing long-haulers to ME/CFS. Fatigue: Biomed Health Behav. 2021:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8411893</ArticleId><ArticleId IdType="pubmed">34484973</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Hermosillo J.A., Mart&#xed;nez-L&#xf3;pez J.P., Carrillo-Lamp&#xf3;n S.A., Ruiz-Ojeda D., Herrera-Ram&#xed;rez S., Amezcua-Guerra L.M., et al. Post-acute COVID-19 symptoms, a potential link with myalgic encephalomyelitis/chronic fatigue syndrome: a 6-month survey in a Mexican cohort. Brain Sci. 2021;11(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8227652</ArticleId><ArticleId IdType="pubmed">34201087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes Rivera M., Mastronardi C., Silva-Aldana C.T., Arcos-Burgos M., Lidbury B.A. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics (Basel) 2019;9(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787585</ArticleId><ArticleId IdType="pubmed">31394725</ArticleId></ArticleIdList></Reference><Reference><Citation>Maksoud R., du Preez S., Eaton-Fitch N., Thapaliya K., Barnden L., Cabanas H., et al. A systematic review of neurological impairments in myalgic encephalomyelitis/ chronic fatigue syndrome using neuroimaging techniques. PLoS ONE. 2020;15(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192498</ArticleId><ArticleId IdType="pubmed">32353033</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan Z.Y., Barnden L.R., Kwiatek R.A., Bhuta S., Hermens D.F., Lagopoulos J. Neuroimaging characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review. J Transl Med. 2020;18(1):335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7466519</ArticleId><ArticleId IdType="pubmed">32873297</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnden L.R., Shan Z.Y., Staines D.R., Marshall-Gradisnik S., Finegan K., Ireland T., et al. Intra brainstem connectivity is impaired in chronic fatigue syndrome. Neuroimage Clin. 2019;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6835065</ArticleId><ArticleId IdType="pubmed">31671321</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan Z.Y., Kwiatek R., Burnet R., Del Fante P., Staines D.R., Marshall-Gradisnik S.M., et al. Medial prefrontal cortex deficits correlate with unrefreshing sleep in patients with chronic fatigue syndrome. NMR Biomed. 2017;30(10)</Citation><ArticleIdList><ArticleId IdType="pubmed">28661067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes D.L., Holdsworth L., Jawad N., Gunasekera P., Morice A.H., Crooks M.G. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung. 2021;199(2):113&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Narazaki M., Masuda K., Kishimoto T. Regulation of IL-6 in immunity and diseases. Adv Exp Med Biol. 2016;941:79&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">27734409</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berg F.M., et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197627</ArticleId><ArticleId IdType="pubmed">32352535</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann V.O., Carerj M.L., Wieters I., Fahim M., Arendt C., Hoffmann J., et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(11):1265&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker R.C. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020;50(3):499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7373848</ArticleId><ArticleId IdType="pubmed">32700024</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M., Dirksen A., Taraborrelli P., Torocastro M., Panagopoulos D., Sutton R., et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond) 2021;21(1):e63&#x2013;e67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzini S., Albergati A., Capelli E., Lorusso L., Gazzaruso C., Pelissero G., et al. Cardiovascular characteristics of chronic fatigue syndrome. Biomed Rep. 2018;8(1):26&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5772628</ArticleId><ArticleId IdType="pubmed">29399336</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Sullivan O. Long-term sequelae following previous coronavirus epidemics. Clin Med (Lond) 2021;21(1):e68&#x2013;e70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850177</ArticleId><ArticleId IdType="pubmed">33144403</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol. 2020;18(8):1663&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141637</ArticleId><ArticleId IdType="pubmed">32278065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S.H., Lui R.N., Sung J.J. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">32215956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegazy M.A., Lithy R.M., Abdel-Hamid H.M., Wahba M., Ashoush O.A., Hegazy M.T., et al. COVID-19 disease outcomes: does gastrointestinal burden play a role? Clin Exp Gastroenterol. 2021;14:199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164348</ArticleId><ArticleId IdType="pubmed">34079323</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.Y., Chen C.Y. How is the digestive system affected by coronavirus disease? J Chin Med Assoc. 2020;83(9):795&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434013</ArticleId><ArticleId IdType="pubmed">32568971</ArticleId></ArticleIdList></Reference><Reference><Citation>Babic T., Browning K.N. The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur J Pharmacol. 2014;722:38&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893663</ArticleId><ArticleId IdType="pubmed">24184670</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff A., Kavanaugh M., Ramgobin D., McClafferty B., Aggarwal C.S., Golamari R., et al. Gastrointestinal manifestations of COVID-19: a review of what we know. Ochsner J. 2021;21(2):177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238098</ArticleId><ArticleId IdType="pubmed">34239378</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C.-Y., Zhang F., Liu Q., Li A.Y., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y.L., Zhan H., et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944&#x2013;955.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Leunis J.C., Geffard M., Berk M. Evidence for the existence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with and without abdominal discomfort (irritable bowel) syndrome. Neuro Endocrinol Lett. 2014;35(6):445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">25433843</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Preez S., Corbitt M., Cabanas H., Eaton N., Staines D., Marshall-Gradisnik S. A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis. Systematic Reviews. 2018;7(1):241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6302292</ArticleId><ArticleId IdType="pubmed">30572962</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh-Messinger J., Manis H., Vrabec A., Sizemore Bs J., Bishof K., Debidda M., et al. The kids are not alright: a preliminary report of Post-COVID syndrome in university students. J Am Coll Health. 2021:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8742843</ArticleId><ArticleId IdType="pubmed">34242539</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B., Siqueira S., de Assis Soares W.R., de Souza Rangel F., Santos N.O., Dos Santos Freitas A., et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q., Wu X., Zheng X., Luo S., Xu S., Weng J. Targeting inflammation and cytokine storm in COVID-19. Pharmacol Res. 2020;159</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320704</ArticleId><ArticleId IdType="pubmed">32603772</ArticleId></ArticleIdList></Reference><Reference><Citation>Segatto M., Fittipaldi R., Pin F., Sartori R., Dae Ko K., Zare H., et al. Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival. Nat Commun. 2017;8(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700099</ArticleId><ArticleId IdType="pubmed">29167426</ArticleId></ArticleIdList></Reference><Reference><Citation>NIHR, A dynamic review of the evidence around ongoing covid-19 symptoms (often called long covid). https://evidence.nihr.ac.uk/themedreview/living-with-covid19; 2020).</Citation></Reference><Reference><Citation>Williams TC, Burgers WA. SARS-CoV-2 evolution and vaccines: cause for concern? Lancet Respir Med.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009632</ArticleId><ArticleId IdType="pubmed">33524316</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Hamilton F.W., Milne A., Morley A.J., Viner J., Attwood M., et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76(4):399&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Linschoten M., Asselbergs F.W. CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic. Eur Heart J. 2020;41(19):1795&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184392</ArticleId><ArticleId IdType="pubmed">32267494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama I. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther. 2020;14(5):259&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">33116043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., &#xc7;al&#x131;&#x15f;kan D.M., Janowski J., Faist A., Conrad B.C.G., Lange J., et al. Beyond vaccines: clinical status of prospective COVID-19 therapeutics. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8519339</ArticleId><ArticleId IdType="pubmed">34659259</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira B.A., Alves Rodrigues Santos S.A., Menezes Pereira E.W., Nogueira A.B., Vieira Neto A.E., de Melo J&#xfa;nior J.M.A., et al. Orofacial Antinociceptive effect of nifedipine in rodents is mediated by TRPM3, TRPA1, and NMDA processes. J Oral Facial Pain Headache. 2020;34(2):174&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">32255583</ArticleId></ArticleIdList></Reference><Reference><Citation>Solaimanzadeh I. Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19. Cureus. 2020;12(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219014</ArticleId><ArticleId IdType="pubmed">32411566</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H., Muraki K., Eaton-Fitch N., Staines D.R., Marshall-Gradisnik S. Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8313851</ArticleId><ArticleId IdType="pubmed">34326841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H., Muraki K., Staines D., Marshall-Gradisnik S. Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients. Front Immunol. 2019;10:2545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6834647</ArticleId><ArticleId IdType="pubmed">31736966</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioh W., Chabane M., Tourette C., Azbekyan A., Morelot-Panzini C., Hajjar L.A., et al. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797700</ArticleId><ArticleId IdType="pubmed">33430924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W., Yang X., Yang D., Bao J., Li R., Xiao Y., et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356137</ArticleId><ArticleId IdType="pubmed">32660650</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biasi S., Meschiari M., Gibellini L., Bellinazzi C., Borella R., Fidanza L., et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020;11(1):3434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7338513</ArticleId><ArticleId IdType="pubmed">32632085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Dai T., Zhou X., Qian H., Guo R., Lei L., et al. Naturally activated adaptive immunity in COVID-19 patients. J Cell Mol Med. 2020;24(21):12457&#x2013;12463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537162</ArticleId><ArticleId IdType="pubmed">32975374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cliff J.M., King E.C., Lee J.S., Sep&#xfa;lveda N., Wolf A.S., Kingdon C., et al. Cellular immune function in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Front Immunol. 2019;10:796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477089</ArticleId><ArticleId IdType="pubmed">31057538</ArticleId></ArticleIdList></Reference><Reference><Citation>Sep&#xfa;lveda N., Carneiro J., Lacerda E., Nacul L. Myalgic encephalomyelitis/chronic fatigue syndrome as a hyper-regulated immune system driven by an interplay between regulatory T cells and chronic human herpesvirus infections. Front Immunol. 2019;10:2684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6883905</ArticleId><ArticleId IdType="pubmed">31824487</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalfaoglu B., Almeida-Santos J., Tye C.A., Satou Y., Ono M. T-cell hyperactivation and paralysis in severe COVID-19 infection revealed by single-cell analysis. Front Immunol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596772</ArticleId><ArticleId IdType="pubmed">33178221</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T., Zhao J., Wang X., Meng Y., Zhao Z., Bao R., et al. CXCL4 promoted the production of CD4(+)CD25(+)FOXP3(+)treg cells in mouse sepsis model through regulating STAT5/FOXP3 pathway. Autoimmunity. 2020;53(5):289&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">32538218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeannet R., Daix T., Formento R., Feuillard J., Fran&#xe7;ois B. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. Intensive Care Med. 2020;46(9):1769&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276497</ArticleId><ArticleId IdType="pubmed">32514592</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L., et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Front Immunol. 2020;11:827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Bosmans E., Kubera M. Increased expression of activation antigens on CD8+ T lymphocytes in Myalgic Encephalomyelitis/chronic fatigue syndrome: inverse associations with lowered CD19+ expression and CD4+/CD8+ ratio, but no associations with (auto)immune, leaky gut, oxidative and nitrosative stress biomarkers. Neuro Endocrinol Lett. 2015;36(5):439&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">26707044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardcastle S.L., Brenu E.W., Johnston S., Nguyen T., Huth T., Ramos S., et al. Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. J Transl Med. 2015;13:299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568602</ArticleId><ArticleId IdType="pubmed">26370228</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosaimi R.A., Albalwi R. Acute upper limb ischemia in a patient with COVID-19 pneumonia. Clin Med. 2020;7</Citation></Reference><Reference><Citation>Fathi F., Sami R., Mozafarpoor S., Hafezi H., Motedayyen H., Arefnezhad R., et al. Immune system changes during COVID-19 recovery play key role in determining disease severity. Int J Immunopathol Pharmacol. 2020;34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594220</ArticleId><ArticleId IdType="pubmed">33076729</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher M.A., Zeng X.R., Barnes Z., Levis S., Klimas N.G. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med. 2009;7:96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779802</ArticleId><ArticleId IdType="pubmed">19909538</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Harding S., Sorenson M., Jason L.A., Maher K., Fletcher M.A. Evidence for T-helper 2 shift and association with illness parameters in chronic fatigue syndrome (CFS) Bull IACFS ME. 2008;16(3):19&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018761</ArticleId><ArticleId IdType="pubmed">21234277</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick G., Fuite J., Kreitz A., Vernon S.D., Klimas N., Fletcher M.A. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010;24(7):1209&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939140</ArticleId><ArticleId IdType="pubmed">20447453</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Nie S., Zhang Z., Zhang Z. Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019. J Infect Dis. 2020;222(2):183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197530</ArticleId><ArticleId IdType="pubmed">32358956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A.M., Ariza M.E., Williams M., Jason L., Beqaj S., Fitzgerald J.T., et al. Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset. PLoS ONE. 2012;7(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498272</ArticleId><ArticleId IdType="pubmed">23155374</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther S., Loebel M., Mooslechner A.A., Knops M., Hanitsch L.G., Grabowski P., et al. Frequent IgG subclass and mannose binding lectin deficiency in patients with chronic fatigue syndrome. Hum Immunol. 2015;76(10):729&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">26429318</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Fu H., Zhu R., Wu X., Ji X., Li X., et al. BRD4 contributes to LPS-induced macrophage senescence and promotes progression of atherosclerosis-associated lipid uptake. Aging (Albany NY) 2020;12(10):9240&#x2013;9259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7288959</ArticleId><ArticleId IdType="pubmed">32392533</ArticleId></ArticleIdList></Reference><Reference><Citation>Juno J.A., Tan H.X., Lee W.S., Reynaldi A., Kelly H.G., Wragg K., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020;26(9):1428&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">32661393</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley A.S., Ford B., Bansal A.S. Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Exp Immunol. 2013;172(1):73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719933</ArticleId><ArticleId IdType="pubmed">23480187</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J.R. Epstein-barr virus induced gene-2 upregulation identifies a particular subtype of chronic fatigue syndrome/myalgic encephalomyelitis. Front Pediatr. 2019;7:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6424879</ArticleId><ArticleId IdType="pubmed">30918887</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensah F.F.K., Armstrong C.W., Reddy V., Bansal A.S., Berkovitz S., Leandro M.J., et al. CD24 expression and B cell maturation shows a novel link with energy metabolism: potential implications for patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front Immunol. 2018;9:2421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204382</ArticleId><ArticleId IdType="pubmed">30405620</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X.H., Zhu Y., Mao J., Du R.C. T cell immunobiology and cytokine storm of COVID-19. Scand J Immunol. 2021;93(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645942</ArticleId><ArticleId IdType="pubmed">33113222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Xie J., Yin M., Yang Y., Ding C., Gao Y., et al. Interleukin-6 and severity of COVID-19 patients in Hefei, China. Med Mal Infect. 2020;50(7):629&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316053</ArticleId><ArticleId IdType="pubmed">32593746</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu E.W., van Driel M.L., Staines D.R., Ashton K.J., Ramos S.B., Keane J., et al. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med. 2011;9:81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120691</ArticleId><ArticleId IdType="pubmed">21619669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijs J., Nees A., Paul L., De Kooning M., Ickmans K., Meeus M., et al. Altered immune response to exercise in patients with chronic fatigue syndrome/myalgic encephalomyelitis: a systematic literature review. Exerc Immunol Rev. 2014;20:94&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">24974723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J.R., Tyrrell D.A. Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome. Curr Pain Headache Rep. 2003;7(5):333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12946285</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser J., Graffelman W., Blauw B., Haspels I., Lentjes E., de Kloet E.R., et al. LPS-induced IL-10 production in whole blood cultures from chronic fatigue syndrome patients is increased but supersensitive to inhibition by dexamethasone. J Neuroimmunol. 2001;119(2):343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11585638</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi H., Suzuki M., Maeda H., Nakamura Y., Ikegami Y., Takenaka Y., et al. Differential diagnosis of COVID-19: importance of measuring blood lymphocytes, serum electrolytes, and olfactory and taste functions. Tohoku J Exp Med. 2020;252(2):109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">33028754</ArticleId></ArticleIdList></Reference><Reference><Citation>Groven N., Fors E.A., Reitan S.K. Patients with fibromyalgia and chronic fatigue syndrome show increased hsCRP compared to healthy controls. Brain Behav Immun. 2019;81:172&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">31176728</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge R., Sartor M.L., Scott F., Cleare A.J. Inflammatory proteins are altered in chronic fatigue syndrome-A systematic review and meta-analysis. Neurosci Biobehav Rev. 2019;107:69&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">31465778</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman T.L., Swartz T.H. Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol. 2020;11:1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324760</ArticleId><ArticleId IdType="pubmed">32655582</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno Fern&#xe1;ndez-Ayala D.J., Navas P., L&#xf3;pez-Lluch G. Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Exp Gerontol. 2020;142</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648491</ArticleId><ArticleId IdType="pubmed">33171276</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood E., Hall K.H., Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 'long-haulers'? Chronic Dis Transl Med. 2021;7(1):14&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680046</ArticleId><ArticleId IdType="pubmed">33251031</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandarano A.H., Maya J., Giloteaux L., Peterson D.L., Maynard M., Gottschalk C.G., et al. Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. J Clin Invest. 2020;130(3):1491&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269566</ArticleId><ArticleId IdType="pubmed">31830003</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnotta V., Ferrigno R., Martino M., Barbot M., Isidori A.M., Scaroni C., et al. Glucocorticoid excess and COVID-19 disease. Rev Endocr Metab Disord. 2020:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538187</ArticleId><ArticleId IdType="pubmed">33025384</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini B.M., Maia I.S., Cavalcanti A.B., Berwanger O., Rosa R.G., Veiga V.C., et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser J., Blauw B., Hinloopen B., Brommer E., de Kloet E.R., Kluft C., et al. CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. J Infect Dis. 1998;177(2):451&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466535</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>